Company: BIAF
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023405
Chunk: 28

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 8
Chunk 28
---
4 

    Research and development 
    $—  
    $30,605  
    $12,916  
    $87,832 
  
    Selling, General and administrative 
     67,132  
     155,082  
     592,439  
     667,762 
  
    Total stock-based compensation
    expense 
    $67,132  
    $185,687  
    $605,355  
    $755,594 

The
following table summarizes stock option activity under the 2014 Plan and 2024 Plan:

SUMMARY OF OPTION ACTIVITY

    Number of  options  
    Weighted-average  exercise price  
    Weighted-average  remaining contractual  term (in years)  
    Aggregate  intrinsic value 
  
    Outstanding at December 31, 2024 
     9,649  
    $207.84  
     4.45  
     — 
  
    Granted 
     —  
     —  
     —  
     — 
  
    Exercised 
     —  
     —  
     —  
     — 
  
    Forfeited 
     (594) 
     147.28  
     —  
     — 
  
    Outstanding at September 30, 2025 
     9,055  
    $211.82  
     3.90  
     — 

    Vested and exercisable at September 30, 2025 
     9,055  
    $211.82  
     3.90  
     — 

As
of September 30, 2025, there was no unrecognized compensation cost related to non-vested stock options.

The
following table summarizes restricted stock award activity under the 2014 Plan and 2024 Plan:

SUMMARY OF RESTRICTED STOCK AWARD

    Number of  

    As of September 30, 2025 

    restricted  stock awards  (RSA)  
    Weighted-  average  grant price  
    FMV on  grant date  
    Vested  number  of RSA  
    Unvested  number  of RSA 
  
    Balance at December 31, 2024 
     44,107  
    $57.08